drugset / Trial / NCT00591188

Capecitabine and Interferon-Alpha in Metastatic Renal Cell Carcinoma Patients With Failure on Interleukin-2 Based Regimens

NCT00591188

Phase 2 Completed 49 enrolled Kidney Cancer Research Bureau
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The aim of this study is to determine preliminary efficacy of capecitabine and interferon-alpha in second-line after interleukin-2 based regimens in patients with MRCC

Timeline

Start
2006-12
Primary completion
2008-05
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Capecitabine Small molecule
Subject interferon alfa-2b Protein / enzyme biologic

Indications